A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

Recruiting now · Phase 1

Conditions studied: Sjögren, Sjogren Disease, Sjogren's Syndrome

In brief

A phase 1b, open-label study of CLN-978 administered subcutaneously in patients with active, moderate to severe Sjogren's Disease.

Key facts

Study ID

NCT07041099

Run by

Cullinan Therapeutics Inc.

People needed

36

Starts

2025-10-01

Expected to finish

2029-03-15

Last updated by the study team

2026-03-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cullinan Investigative Site — Orlando, Florida, United States (enrolling)
• Cullinan Investigative Site — Memphis, Tennessee, United States (enrolling)
• Cullinan Investigative Site — Plano, Texas, United States (enrolling)
• Cullinan Investigative Site — Webster, Texas, United States (enrolling)
• Cullinan Investigative Site — Salt Lake City, Utah, United States (enrolling)
• Cullinan Investigative Site — Brest, France (enrolling)
• Cullinan Investigative Site — Le Kremlin-Bicêtre, France (enrolling)
• Cullinan Investigative Site — Strasbourg, France (enrolling)
• Cullinan Investigative Site — Erlangen, Germany (enrolling)
• Cullinan Investigative Site — Hanover, Germany (enrolling)
• Cullinan Investigative Site — Roma, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.